Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 859 across all filing types
Latest filing 2018-06-14 Director's Dealing
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-06-14 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 11, 2018, reporting the entry into a material definitive agreement related to an underwriting agreement for the sale of shares by a selling shareholder. It includes details about the underwriting agreement, the parties involved, and the terms of the offering. The document does not contain financial statements or quarterly/annual financial results but is an announcement of a financing transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2018-06-13 English
424B7
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(7) related to a stock offering by Medpace Holdings, Inc. It details the sale of 3,000,000 shares by a selling shareholder, including pricing, underwriting discounts, and other offering terms. The document references the company's 2017 10-K and 2018 First Quarter 10-Q reports but does not itself contain financial statements or detailed financial performance data. Instead, it is a disclosure document related to capital raising activities. Therefore, it fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities.
2018-06-13 English
424B7
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(7) under the Securities Act, related to a registration statement for the sale of common stock by a selling shareholder. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and legal matters. The document is a disclosure related to capital raising and securities offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a substantive filing related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is a full filing, not a brief announcement or certification.
2018-06-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text discusses an immaterial misstatement related to the adoption of ASC 606 revenue recognition standards and references prior filings such as the 10-Q and 10-K but does not contain full financial statements or comprehensive financial performance data itself. It is not an Annual Report (10-K), Interim Report (10-Q/IR), or Earnings Release (ER). The document is not a certification or attestation letter, so it is not a Regulatory Filing (RNS) under the certification rule. The document is a standalone report announcing a specific event or correction, typical of an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other categories.
2018-06-08 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing dated May 18, 2018, reporting the submission of matters to a vote of security holders at the 2018 Annual Meeting of Stockholders. It includes detailed voting results for the election of directors and ratification of the independent auditor. The content focuses on official voting results from a shareholder meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3597 characters, which is relatively short but contains substantive voting data, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). The presence of voting results and the nature of the content clearly indicate classification as DVA.
2018-05-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.